Last reviewed · How we verify

NCT01151592: ASSURED

Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)

Withdrawn Phase 4 Last updated 24 January 2018
What this trial tests

Phase 4 trial testing Iron Sucrose in Iron Deficiency Anemia. Withdrawn.

Quick facts

Lead sponsorAmerican Regent, Inc.
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

American Regent, Inc. — full company profile →

Who can join

18 and older, any sex, with Iron Deficiency Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess the safety and tolerability of Venofer in patients with chronic kidney disease who cannot tolerate Ferumoxytol (Feraheme) or intravenous iron containing a dextran (INFed or Dexferrum).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Iron Sucrose

Trials testing the same drug.

Other recruiting trials for Iron Deficiency Anemia

Currently open trials in the same condition.

Other American Regent, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01151592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing